Cargando…

Current Status and Future Perspectives of Perioperative Therapy for Resectable Biliary Tract Cancer: A Multidisciplinary Review

SIMPLE SUMMARY: For decades, there has been no globally accepted neoadjuvant or adjuvant therapy in resectable biliary tract cancer. Based on the results of the BILCAP trial, adjuvant capecitabine has been widely regarded as standard adjuvant therapy. Focusing on the management of resectable biliary...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yoo, Changhoon, Shin, Sang Hyun, Park, Joon-Oh, Kim, Kyu-Pyo, Jeong, Jae Ho, Ryoo, Baek-Yeol, Lee, Woohyung, Song, Ki-Byung, Hwang, Dae-Wook, Park, Jin-hong, Lee, Jae Hoon
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8037230/ https://www.ncbi.nlm.nih.gov/pubmed/33916008 http://dx.doi.org/10.3390/cancers13071647

Ejemplares similares

Reduced and Normalized Carbohydrate Antigen 19-9 Concentrations after Neoadjuvant Chemotherapy Have Comparable Prognostic Performance in Patients with Borderline Resectable and Locally Advanced Pancreatic Cancer
por: Lee, Woohyung, et al.
Publicado: (2020)

Efficacy of fluoropyrimidine-based chemotherapy in patients with advanced biliary tract cancer after failure of gemcitabine plus cisplatin: retrospective analysis of 321 patients
por: Kim, Bum Jun, et al.
Publicado: (2017)

Feasibility of HER2-Targeted Therapy in Advanced Biliary Tract Cancer: A Prospective Pilot Study of Trastuzumab Biosimilar in Combination with Gemcitabine Plus Cisplatin
por: Jeong, Hyehyun, et al.
Publicado: (2021)

Clinical Benefit of Maintenance Therapy for Advanced Biliary Tract Cancer Patients Showing No Progression after First-Line Gemcitabine Plus Cisplatin
por: Hyung, Jaewon, et al.
Publicado: (2019)

Efficacy and Safety of Pembrolizumab in Patients with Refractory Advanced Biliary Tract Cancer: Tumor Proportion Score as a Potential Biomarker for Response
por: Kang, Junho, et al.
Publicado: (2020)

FOLFIRINOX in borderline resectable and locally advanced unresectable pancreatic adenocarcinoma
por: Yoo, Changhoon, et al.
Publicado: (2020)

Multicenter Phase II Study of Oxaliplatin, Irinotecan, and S-1 as First-line Treatment for Patients with Recurrent or Metastatic Biliary Tract Cancer
por: Yoo, Changhoon, et al.
Publicado: (2018)

Prognostic Impact of Perioperative CA19-9 Levels in Patients with Resected Perihilar Cholangiocarcinoma
por: Lee, Jong Woo, et al.
Publicado: (2021)

Spatial Distribution and Prognostic Implications of Tumor-Infiltrating FoxP3(−) CD4(+) T Cells in Biliary Tract Cancer
por: Kim, Hyung-Don, et al.
Publicado: (2021)

Real-world outcomes of adjuvant gemcitabine versus gemcitabine plus capecitabine for resected pancreatic ductal adenocarcinoma
por: Kang, Sora, et al.
Publicado: (2022)

Adjuvant Chemotherapy for Resected Ampulla of Vater Carcinoma: Retrospective Analysis of 646 Patients
por: Kim, Jwa Hoon, et al.
Publicado: (2021)

Neoadjuvant modified FOLFIRINOX followed by postoperative gemcitabine in borderline resectable pancreatic adenocarcinoma: a Phase 2 study for clinical and biomarker analysis
por: Yoo, Changhoon, et al.
Publicado: (2020)

Efficacy and safety of neoadjuvant FOLFIRINOX for borderline resectable pancreatic adenocarcinoma: improved efficacy compared with gemcitabine-based regimen
por: Yoo, Changhoon, et al.
Publicado: (2017)

Analysis of Plasma Circulating Tumor DNA in Borderline Resectable Pancreatic Cancer Treated with Neoadjuvant Modified FOLFIRINOX: Clinical Relevance of DNA Damage Repair Gene Alteration Detection
por: Lim, Dong-Hoon, et al.
Publicado: (2023)

Survival Benefit of Adjuvant Chemotherapy in Patients with Pancreatic Ductal Adenocarcinoma Who Underwent Surgery Following Neoadjuvant FOLFIRINOX
por: Lee, So Heun, et al.
Publicado: (2023)

Clinical Outcomes of Conversion Surgery after Neoadjuvant Chemotherapy in Patients with Borderline Resectable and Locally Advanced Unresectable Pancreatic Cancer: A Single-Center, Retrospective Analysis
por: Yoo, Changhoon, et al.
Publicado: (2019)

Efficacy of Chemotherapy in Patients with Unresectable or Metastatic Pancreatic Acinar Cell Carcinoma: Potentially Improved Efficacy with Oxaliplatin-Containing Regimen
por: Yoo, Changhoon, et al.
Publicado: (2017)

Clinical outcomes of liposomal irinotecan plus fluorouracil/leucovorin for metastatic pancreatic adenocarcinoma in patients previously treated with conventional irinotecan-containing chemotherapy
por: Bang, Kyunghye, et al.
Publicado: (2021)

Impact of radiologic splenic vessel invasion in resectable left-sided pancreatic ductal adenocarcinoma: predictor of early systemic recurrence following upfront surgery
por: Lee, Seung Jae, et al.
Publicado: (2022)

Comparison of perioperative outcomes in pancreatic head cancer patients following either a laparoscopic or open pancreaticoduodenectomy with a superior mesenteric artery first approach
por: Park, Min Young, et al.
Publicado: (2021)

Establishing Patient-Derived Cancer Cell Cultures and Xenografts in Biliary Tract Cancer
por: Kang, Jihoon, et al.
Publicado: (2023)

Comparison of Characteristics and Survival Rates of Resectable Pancreatic Ductal Adenocarcinoma according to Tumor Location
por: Sung, Min Kyu, et al.
Publicado: (2021)

Bile Acid Analysis in Biliary Tract Cancer
por: Park, Jeong Youp, et al.
Publicado: (2006)

Real-world data analysis of patients with cancer of unknown primary
por: Kang, Sora, et al.
Publicado: (2021)

Role of Dedicated Subspecialized Radiologists in Multidisciplinary Team Discussions on Lower Gastrointestinal Tract Cancers
por: Jeon, Sun Kyung, et al.
Publicado: (2022)

Prognosis of Pancreatic Cancer Patients with Synchronous or Metachronous Malignancies from Other Organs Is Better than Those with Pancreatic Cancer Only
por: Shin, Su-Jin, et al.
Publicado: (2018)

Radiation therapy for recurrent extrahepatic bile duct cancer
por: Koh, Minji, et al.
Publicado: (2021)

Expression of HER2 and Mismatch Repair Proteins in Surgically Resected Gallbladder Adenocarcinoma
por: Sung, You-Na, et al.
Publicado: (2021)

A Phase II Study to Compare the Safety and Efficacy of Direct Oral Anticoagulants versus Subcutaneous Dalteparin for Cancer-Associated Venous Thromboembolism in Patients with Advanced Upper Gastrointestinal, Hepatobiliary and Pancreatic Cancer: PRIORITY
por: Kim, Jwa Hoon, et al.
Publicado: (2022)

Biliary ascariasis misidentified as a biliary stent in a patient undergoing liver resection
por: Chae, Hochang, et al.
Publicado: (2023)

Arterial resection during pancreatectomy for pancreatic ductal adenocarcinoma with arterial invasion: A single-center experience with 109 patients
por: Kwon, Jaewoo, et al.
Publicado: (2020)

Efficacy and safety of second-line nab-paclitaxel plus gemcitabine after progression on FOLFIRINOX for unresectable or metastatic pancreatic ductal adenocarcinoma: multicenter retrospective analysis
por: Chae, Heejung, et al.
Publicado: (2020)

Current progress in perioperative chemotherapy for biliary tract cancer
por: Ioka, Tatsuya, et al.
Publicado: (2023)

Prognostic Factors and Scoring Model for Survival in Metastatic Biliary Tract Cancer
por: Park, Hyung Soon, et al.
Publicado: (2017)

Lack of Association between Postoperative Pancreatitis and Other Postoperative Complications Following Pancreaticoduodenectomy
por: Yoo, Daegwang, et al.
Publicado: (2021)

Dynamic changes in peripheral blood monocytes early after anti-PD-1 therapy predict clinical outcomes in hepatocellular carcinoma
por: Jeon, Seung Hyuck, et al.
Publicado: (2022)

Circulating tumour cells as an indicator of early and systemic recurrence after surgical resection in pancreatic ductal adenocarcinoma
por: Park, Yejong, et al.
Publicado: (2021)

Stereotactic body radiation therapy for locally advanced pancreatic cancer
por: Jung, Jinhong, et al.
Publicado: (2019)

Clinical Outcomes of Second-Line Chemotherapy after Progression on Nab-Paclitaxel Plus Gemcitabine in Patients with Metastatic Pancreatic Adenocarcinoma
por: Lee, Kyoungmin, et al.
Publicado: (2020)

Efficacy of Imatinib in Patients with Platelet-Derived Growth Factor Receptor Alpha–Mutated Gastrointestinal Stromal Tumors
por: Yoo, Changhoon, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_m5tufniefi7acfr8c8d8r0cric